Nektar Therapeutics (NASDAQ:NKTR) Receives $2.33 Average Price Target from Analysts

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has earned an average recommendation of “Hold” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One… [+3388 chars]

Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

For Girls to Succeed in STEM, Confidence Matters as Much as Competence
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical